EPRX (Eupraxia Pharmaceuticals Inc.) Stock Market Reviews

crown

search

Read and share opinions on EPRX (Eupraxia Pharmaceuticals Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock m

EPRX

Eupraxia Pharmaceuticals Inc.

clarify Biotechnology

bookmark Healthcare

public Canada

Sell Neutral Buy

Latest News

Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet
Nov 14, 2025
Eupraxia Pharmaceuticals Posts Wider Q3 Loss, Has Sufficient Cash on Hand To Fund It Into H1 2028
Nov 4, 2025
Eupraxia Pharmaceuticals Inc. (EPRX) is a Great Momentum Stock: Should You Buy?
Oct 14, 2025
Eupraxia Pharmaceuticals Inc. (EPRX) Upgraded to Buy: Here's Why
Oct 14, 2025
Wall Street Analysts Believe Eupraxia Pharmaceuticals Inc. (EPRX) Could Rally 85.12%: Here's is How to Trade
Oct 14, 2025
Eupraxia Pharmaceuticals Up 20% After Hours Following 'Positive' Data From Eosinophilic Esophagitis Trial
Sep 29, 2025
Independent Director of Eupraxia Pharmaceuticals Picks Up 13% More Stock
Sep 28, 2025
Eupraxia Raises US$80.5 Million in Public Offering to Fund Clinical Pipeline, Shares Slip 4%
Sep 24, 2025
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
Sep 24, 2025
Eupraxia Prices US$70M Share Offering at $5.50; U.S.-Listed Shares Fall 13% Pre-Market
Sep 23, 2025
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares
Sep 23, 2025
Eupraxia Pharmaceuticals Down 2.6% After Hours as It Files for Public Offering of Common Shares
Sep 22, 2025
Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares
Sep 22, 2025
Eupraxia Reports Positive 12-Month Results From RESOLVE Trial
Sep 2, 2025

Reviews